Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue of 2.7 million euros for the first quarter of 2013 (3.0 million euros in 1Q2012). The source of this revenue is Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb, signed in July 2011.
Cash, cash equivalents and current financial instruments of the Company amounted to 28.4 million euros at March 31, 2013. As at the same date, the financial liabilities of the Company amounted to 4.4 million euros.
Activity report and Reference Document:
The French version of the 2012 Reference Document, including the Annual Financial Report, is available on the Company’s website.
The English version of the 2012 Reference Document will be made available on Innate Pharma’s website in May 2012.
The Activity and Responsibility report is already available on Innate Pharma’s website, in French and in English.
Hard copies of these documents are available upon request to the investor relations department of the Company.